EDIT vs. NVAX, FUSN, CGEM, EXAI, CCCC, FATE, ALLO, ALEC, HLVX, and REPL
Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Novavax (NVAX), Fusion Pharmaceuticals (FUSN), Cullinan Oncology (CGEM), Exscientia (EXAI), C4 Therapeutics (CCCC), Fate Therapeutics (FATE), Allogene Therapeutics (ALLO), Alector (ALEC), HilleVax (HLVX), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.
Editas Medicine (NASDAQ:EDIT) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Editas Medicine has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Editas Medicine currently has a consensus target price of $15.00, indicating a potential upside of 94.30%. Novavax has a consensus target price of $17.00, indicating a potential upside of 230.74%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than Editas Medicine.
Editas Medicine has higher earnings, but lower revenue than Novavax. Editas Medicine is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Novavax received 540 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 74.29% of users gave Novavax an outperform vote while only 54.04% of users gave Editas Medicine an outperform vote.
Novavax has a net margin of -55.41% compared to Editas Medicine's net margin of -196.12%. Novavax's return on equity of 0.00% beat Editas Medicine's return on equity.
76.6% of Editas Medicine shares are held by institutional investors. Comparatively, 71.5% of Novavax shares are held by institutional investors. 2.2% of Editas Medicine shares are held by insiders. Comparatively, 0.9% of Novavax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Novavax had 2 more articles in the media than Editas Medicine. MarketBeat recorded 6 mentions for Novavax and 4 mentions for Editas Medicine. Novavax's average media sentiment score of 0.21 beat Editas Medicine's score of 0.17 indicating that Novavax is being referred to more favorably in the news media.
Summary
Novavax beats Editas Medicine on 10 of the 18 factors compared between the two stocks.
Get Editas Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Editas Medicine Competitors List
Related Companies and Tools